Cereno Scientific has received a conditional approval for admission to trading of the Company's shares of series B on Nasdaq First North. Nasdaq's decision is conditional on that (i) nothing occurs in the Company before the first day of trading that could lead to a different assessment by the stock exchange, (ii) the Company updates its website in accordance with Rulebook no later than two days before the first day of trading, and (iii) the Company disclose an additional document before the first day of trading. First day of trading in the Company's shares of series B on Nasdaq First North is scheduled for June 14, 2023. Trading in the Company's shares of series B on Spotlight Stock Market is scheduled to cease and last day of trading on Spotlight Stock Market is scheduled for June 13, 2023. Trading with the warrants of series TO3 is intended to take place after registration of the completed rights issue with the Swedish Companies Registration Office.

Cereno Scientific's shares of series B will continue to be traded under the ticker CRNO B with ISIN code SE0008241558. No new shares will be issued in connection with the admission to trading on Nasdaq First North. The Company's shareholders do not need to take any measures in connection with the list change.

Advisers

Mangold Fondkommission AB is the Company's advisor in connection with the listing on Nasdaq First North and has been appointed as the Company's Certified Adviser. MAQS Advokatbyrå AB acts as legal advisor in connection with the listing on Nasdaq First North.

For further information, please contact:

Jonas Fogelberg, Interim CFO

Email: info@cerenoscientific.com

http://www.cerenoscientific.com/

About Cereno Scientific AB

Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno Scientific to use their cutting-edge technology CardioMEMS HF System in the study. Cereno Scientific also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects. In preclinical studies it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno Scientific is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.